Top

Published in:

01-02-2020 | Metastasis | Original Scientific Report

Does the ATA Risk Stratification Apply to Patients with Papillary Thyroid Microcarcinoma?

Authors: Dessislava I. Stefanova, Arpita Bose, Timothy M. Ullmann, Jessica N. Limberg, Brendan M. Finnerty, Rasa Zarnegar, Thomas J. Fahey III, Toni Beninato

Published in: World Journal of Surgery | Issue 2/2020

Abstract

Background

The incidence of papillary thyroid microcarcinoma (PTMC) has increased over the past decade. The American Thyroid Association (ATA) suggests that these patients may undergo either thyroid lobectomy or active surveillance. It remains unclear whether there exists a subgroup of PTMC patients who may benefit from more aggressive treatment due to increased risk of recurrence.

Methods

We retrospectively reviewed 357 patients with PTMC who underwent surgery at a single institution from 2004 to 2016. Patients were classified according to 2015 ATA risk stratification for structural disease recurrence. Demographic, oncologic, and clinicopathologic data were compared between groups.

Results

Out of 357 patients, 246 were classified as low-risk PTMC, 93 were intermediate-risk, and 18 were high-risk. There were more male patients in the high-risk group (38.9%) than the intermediate- (31.2%) or low-risk groups (15.4%) (p < 0.001). Patients with low-risk microcarcinomas were more likely to have an incidental PTMC when compared to intermediate- or high-risk groups (98[39.8%], 15[16.1%], 1[5.6%], respectively, p < 0.001). Patients with high-risk PTMCs, compared to those with intermediate- and low-risk PTMCs, were more likely to have rising postoperative thyroglobulin levels after total thyroidectomy (6[40.0%], 4[5.1%], 9[5.7%], respectively, p = 0.001) and structural recurrence after lobectomy or total thyroidectomy (3[16.7%], 0[0%], 0[0%], respectively, p < 0.001). The median follow-up time was 17.5 (IQR 3–55) months.

Conclusions

Patients with high-risk PTMC have an increased risk of recurrence when compared to low- and intermediate-risk microcarcinomas, whereas intermediate-risk PTMC may behave similarly to low-risk tumors. ATA risk stratification may inform clinical decision making for patients with PTMC.

Lim H, Devesa SS, Sosa JA et al (2017) Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA 317:1338–1348. https://doi.org/10.1001/jama.2017.2719 CrossRefPubMedPubMedCentral

Davies L, Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295:2164–2167. https://doi.org/10.1001/jama.295.18.2164 CrossRefPubMed

Vigneri R, Malandrino P, Vigneri P (2015) The changing epidemiology of thyroid cancer: why is incidence increasing? Curr Opin Oncol 27:1–7. https://doi.org/10.1097/CCO.0000000000000148 CrossRefPubMed

Leboulleux S, Tuttle RM, Pacini F, Schlumberger M (2016) Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance? Lancet Diabetes Endocrinol 4:933–942. https://doi.org/10.1016/S2213-8587(16)30180-2 CrossRefPubMed

Ito Y, Tomoda C, Uruno T et al (2004) Papillary microcarcinoma of the thyroid: how should it be treated? World J Surg 28:1115–1121. https://doi.org/10.1007/s00268-004-7644-5 CrossRefPubMed

Ito Y, Uruno T, Nakano K et al (2003) An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 13:381–387. https://doi.org/10.1089/105072503321669875 CrossRefPubMed

Sorrentino F, Atzeni J, Romano G et al (2010) Differentiated microcarcinoma of the thyroid gland. G Chir 31:277–278PubMed

Mazzaferri EL (2007) Management of low-risk differentiated thyroid cancer. Endocr Pract 13:498–512. https://doi.org/10.4158/EP.13.5.498 CrossRefPubMed

Frangos S, Iakovou IP, Marlowe RJ et al (2015) Difficulties in deciding whether to ablate patients with putatively “low-intermediate-risk” differentiated thyroid carcinoma: do guidelines mainly apply in the centres that produce them? Results of a retrospective, two-centre quality assurance study. Eur J Nucl Med Mol Imaging 42:2045–2055. https://doi.org/10.1007/s00259-015-3124-4 CrossRefPubMed

10.

Dhir M, McCoy KL, Ohori NP et al (2018) Correct extent of thyroidectomy is poorly predicted preoperatively by the guidelines of the American Thyroid Association for low and intermediate risk thyroid cancers. Surgery 163:81–87. https://doi.org/10.1016/j.surg.2017.04.029 CrossRefPubMed

11.

Gao R, Jia X, Liang Y et al (2019) Papillary thyroid micro carcinoma: the incidence of high-risk features and its prognostic implications. Front Endocrinol (Lausanne) 10:74. https://doi.org/10.3389/fendo.2019.00074 CrossRef

12.

Yu X-M, Wan Y, Sippel RS, Chen H (2011) Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg 254:653–660. https://doi.org/10.1097/SLA.0b013e318230036d CrossRefPubMed

13.

Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26:1–133. https://doi.org/10.1089/thy.2015.0020 CrossRefPubMedPubMedCentral

14.

Kwon H, Jeon MJ, Kim WG et al (2017) A comparison of lobectomy and total thyroidectomy in patients with papillary thyroid microcarcinoma: a retrospective individual risk factor-matched cohort study. Eur J Endocrinol 176:371–378. https://doi.org/10.1530/EJE-16-0845 CrossRefPubMed

15.

Kim TY, Shong YK (2017) Active surveillance of papillary thyroid microcarcinoma: a mini-review from Korea. Endocrinol Metab (Seoul) 32:399–406. https://doi.org/10.3803/EnM.2017.32.4.399 CrossRef

16.

Tuttle RM, Tala H, Shah J et al (2010) Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20:1341–1349. https://doi.org/10.1089/thy.2010.0178 CrossRefPubMedPubMedCentral

17.

Cho J-K, Kim J-Y, Jeong C-Y et al (2012) Clinical features and prognostic factors in papillary thyroid microcarcinoma depends on age. J Korean Surg Soc 82:281–287. https://doi.org/10.4174/jkss.2012.82.5.281 CrossRefPubMedPubMedCentral

18.

Zheng W, Wang X, Rui Z et al (2019) Clinical features and therapeutic outcomes of patients with papillary thyroid microcarcinomas and larger tumors. Nucl Med Commun 40:477–483. https://doi.org/10.1097/MNM.0000000000000991 CrossRefPubMed

19.

Mercante G, Frasoldati A, Pedroni C et al (2009) Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid: results of a study in 445 patients. Thyroid 19:707–716. https://doi.org/10.1089/thy.2008.0270 CrossRefPubMed

20.

Cheng F, Chen Y, Zhu L et al (2019) Risk factors for cervical lymph node metastasis of papillary thyroid microcarcinoma: a single-center retrospective study. Int J Endocrinol 2019:8579828. https://doi.org/10.1155/2019/8579828 CrossRefPubMedPubMedCentral

21.

Jeon MJ, Kim WG, Choi YM et al (2016) Features predictive of distant metastasis in papillary thyroid microcarcinomas. Thyroid 26:161–168. https://doi.org/10.1089/thy.2015.0375 CrossRefPubMed

22.

Siddiqui S, White MG, Antic T et al (2016) Clinical and pathologic predictors of lymph node metastasis and recurrence in papillary thyroid microcarcinoma. Thyroid 26:807–815. https://doi.org/10.1089/thy.2015.0429 CrossRefPubMed

23.

Sugitani I, Fujimoto Y (1999) Symptomatic versus asymptomatic papillary thyroid microcarcinoma: a retrospective analysis of surgical outcome and prognostic factors. Endocr J 46:209–216CrossRefPubMed

24.

Arora N, Turbendian HK, Scognamiglio T, et al. (2008) Extrathyroidal extension is not all equal: Implications of macroscopic versus microscopic extent in papillary thyroid carcinoma. Surgery 144:942–7; discussion 947. doi: 10.1016/j.surg.2008.07.023CrossRefPubMed

25.

Kazaure HS, Roman SA, Sosa JA (2012) Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients. Ann Surg Oncol 19:1874–1880. https://doi.org/10.1245/s10434-011-2129-x CrossRefPubMed

26.

Kuo EJ, Goffredo P, Sosa JA, Roman SA (2013) Aggressive variants of papillary thyroid microcarcinoma are associated with extrathyroidal spread and lymph-node metastases: a population-level analysis. Thyroid 23:1305–1311. https://doi.org/10.1089/thy.2012.0563 CrossRefPubMedPubMedCentral

27.

Brito JP, Ito Y, Miyauchi A, Tuttle RM (2016) A clinical framework to facilitate risk stratification when considering an active surveillance alternative to immediate biopsy and surgery in papillary microcarcinoma. Thyroid 26:144–149. https://doi.org/10.1089/thy.2015.0178 CrossRefPubMedPubMedCentral

28.

Sugitani I, Toda K, Yamada K et al (2010) Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg 34:1222–1231. https://doi.org/10.1007/s00268-009-0359-x CrossRefPubMed

29.

Kim HJ, Kim NK, Choi JH et al (2013) Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 78:614–620. https://doi.org/10.1111/cen.12034 CrossRef

30.

Hu G, Zhu W, Yang W et al (2016) The effectiveness of radioactive iodine remnant ablation for papillary thyroid microcarcinoma: a systematic review and meta-analysis. World J Surg 40:100–109. https://doi.org/10.1007/s00268-015-3346-4 CrossRefPubMed

31.

Durante C, Montesano T, Attard M et al (2012) Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement? J Clin Endocrinol Metab 97:2748–2753. https://doi.org/10.1210/jc.2012-1123 CrossRefPubMed

32.

Ibrahimpasic T, Nixon IJ, Palmer FL et al (2012) Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer–is there a need for radioactive iodine therapy? Surgery 152:1096–1105. https://doi.org/10.1016/j.surg.2012.08.034 CrossRefPubMed

Title: Does the ATA Risk Stratification Apply to Patients with Papillary Thyroid Microcarcinoma?
Authors: Dessislava I. Stefanova
Arpita Bose
Timothy M. Ullmann
Jessica N. Limberg
Brendan M. Finnerty
Rasa Zarnegar
Thomas J. Fahey III
Toni Beninato
Publication date: 01-02-2020
Publisher: Springer International Publishing
Keywords: Metastasis
Neck Dissection
Hemithyroidectomy
Thyroidectomy
Hemithyroidectomy
Thyroidectomy
Published in: World Journal of Surgery / Issue 2/2020
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-019-05215-4

At a glance: The STEP trials

Springer Medicine

Does the ATA Risk Stratification Apply to Patients with Papillary Thyroid Microcarcinoma?

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2020

Biochemical Profile Affects IOPTH Kinetics and Cure Rate in Primary Hyperparathyroidism

Changes in Tracheal Tube Cuff Pressure and Recurrent Laryngeal Nerve Conductivity During Thyroid Surgery

Authors’ Reply: Honorary Authorships in Surgical Literature

Surgical Resection of Pheochromocytomas and Paragangliomas is Associated with Lower Cholesterol Levels

Comparison of Pre- and Post-transplant Parathyroidectomy in Renal Transplant Recipients and the Impact of Parathyroidectomy Timing on Calcium Metabolism and Renal Allograft Function: A Retrospective Single-Center Analysis

The Role of Tumor and Lymph Node Size and Extension in Papillary Thyroid Cancer Staging